CDC, Emerging Infectious Diseases, October 2005
Antimicrobial
Drug Resistance: "Prediction Is Very Difficult, Especially about the Future
Evolution of bacteria towards resistance to antimicrobial drugs, including multidrug
resistance, is unavoidable because it represents a particular aspect of the general
evolution of bacteria that is unstoppable. Over the last 60 years, bacteria and, in
particular, those pathogenic for humans have evolved toward antimicrobial drug resistance.
This evolution has 2 key steps: emergence and dissemination of resistance. October
2005 Issue of Emerging
Infectious DiseasesPlos Biology, June 2005
Inhibition of Mutation and Combating the Evolution of Antibiotic
Resistance
The worldwide emergence of antibiotic-resistant bacteria threatens to undo
the dramatic advances in human health that were ushered in with the discovery of these
drugs in the mid-1900s. Today, resistance has rendered most of the original antibiotics
obsolete for many infections, mandating an increased reliance on synthetic drugs. However,
bacteria also evolve resistance to these drugs, typically by acquiring chromosomal
mutations [16]. Within the classical paradigm that mutations are the inevitable
consequence of replicating a large genome with polymerases of finite fidelity,
resistance-conferring mutations are unavoidable. However, recent evidence suggests that
bacteria may play a more active role in the mutation of their own genomes in response to
at least some DNA-damaging agents by inducing proteins that actually promote mutation
[715]. If the acquisition of antibiotic resistance-conferring mutations also
requires the induction of these proteins, then their inhibition would represent a novel
approach to combating the growing problem of drug resistance.
New England Journal of Medicine, April 7, 2005
Methicillin-Resistant
Staphylococcus aureus Disease in Three Communities
Background Methicillin-resistant Staphylococcus aureus (MRSA) infection has emerged in
patients who do not have the established risk factors. The national burden and clinical
effect of this novel presentation of MRSA disease are unclear. Methods We evaluated MRSA
infections in patients identified from population-based surveillance in Baltimore and
Atlanta and from hospital-laboratorybased sentinel surveillance of 12 hospitals in
Minnesota. Information was obtained by interviewing patients and by reviewing their
medical records. Infections were classified as community-acquired MRSA disease if no
established risk factors were identified.
New England Journal of Medicine, April 7, 2005
Necrotizing Fasciitis Caused by Community-Associated Methicillin-Resistant
Staphylococcus aureus in Los Angeles
Background: Necrotizing fasciitis is a life-threatening infection requiring urgent
surgical and medical therapy. Staphylococcus aureus has been a very uncommon cause of
necrotizing fasciitis, but we have recently noted an alarming number of these infections
caused by community-associated methicillin-resistant S. aureus (MRSA). Methods: We
reviewed the records of 843 patients whose wound cultures grew MRSA at our center from
January 15, 2003, to April 15, 2004. Among this cohort, 14 were identified as patients
presenting from the community with clinical and intraoperative findings of necrotizing
fasciitis, necrotizing myositis, or both.
KQED Public Radio, January 20, 2005
Antibiotics
Antibiotics have been called wonder drugs because of their
effectiveness against some of the world's deadliest diseases. But overuse has caused a
growing problem of antibiotic resistance. We'll explore efforts to cut back on their use,
both in humans and in farm animals. Also, we'll take a look at why there are so few new
antibiotics in the pharmaceutical pipeline and the potential health crisis that looms
ahead.
NPR Public Radio, October 29, 2004
Examining
Antibiotic Resistance
We look at the problem of antibiotic resistant bacteria. Are researchers and manufacturers
doing enough to develop new angles of attack against these medical threats?
Infectious Diseases Society of America, July, 2004
Bad Bugs, No Drugs Executive Summary
The purpose of this document is to call attention to a frightening twist in the
antibiotic resistance problem that has not received adequate attention from federal
policymakers: The pharmaceutical pipeline for new antibiotics is drying up. Full report with recommendations to the US Congress (click the
"download whitepaper" link).
Infectious Diseases Society of America, July, 2004
Urge
Legislators to Spur Antibiotic R&D, Avert Public Health Crisis
Drug companies are withdrawing from antibiotic development
due to unique challenges in this area of medicine. As a result, there is a dwindling
supply of antibiotics available to treat patients with potentially life-threatening
drug-resistant infections. Many policymakers, including Members of Congress, are not
aware of this brewing crisis or its implications for patient care, public health and
national security.
National Institute of Allergy and Infectious
Diseases, April 2004
The
Problem of Antibiotic Resistance
antibiotic resistance has been a problem for nearly as long as we've been using
antibiotics. Not long after the introduction of penicillin, a bacterium known as Staphylococcus
aureus began developing penicillin-resistant strains. Today, antibiotic-resistant
strains of S. aureus bacteria as well as various enterococci-bacteria that colonize
the intestines-are common and pose a global health problem in hospitals. More and more
hospital-acquired infections are resistant to the most powerful antibiotics available,
methicillin and vancomycin. These drugs are reserved to treat only the most intractable
infections in order to slow development of resistance to them.
Medical Journal of Australia, 2004
The dearth of new antibiotic development: why we should be worried
and what we can do about it
- The emergence and spread of multidrug-resistant pathogens has increased substantially
over the past 20 years.
- Over the same period, the development of new antibiotics has decreased alarmingly, with
many pharmaceutical companies pulling out of antibiotic research in favour of developing
lifestyle drugs.
- Reasons given for withdrawing from antibiotic development include poor net present
value status of antibiotics, changes in regulations requiring larger drug trials and
prolonged post-marketing surveillance, clinical preference for narrow-spectrum rather than
broad-spectrum agents, and high new-drug purchase costs.
- Major improvements in infection control in Australia are needed to prevent further
spread of resistant clones, buying some time to develop urgently needed new antibiotic
agents.
- Perpetuating a culture of pharma bashing will simply lead to more
pharmaceutical companies withdrawing from the market. A change in the health and research
culture is needed to improve cooperation between public, academic and private sectors.
Annals of Internal Medicine, April, 1993
Resistance
to Antimicrobial Drugs--A Worldwide Calamity
Resistant bacterial strains have emerged and have spread throughout the world
because of the remarkable genetic plasticity of the microorganisms, heavy
selective pressures of use, and the mobility of the world population. New and
more expensive drugs have appeared almost in the nick of time, but it
is doubtful that they will keep pace. The problem of resistance to
antimicrobial drugs is particularly troublesome in developing countries. The
underlying problems are largely economic and societal, and no ready solutions
are available.
Aware - a Project of the California Medical Association
CDC - Antimicrobal Resistance
CDC - Antibiotic
Resistance
CDC -
Spotlight on Community-Associated MRSA
CDER (FDA) - Antimicrobal Resistance
Consumers Union
National Necrotizing Fasciitis Foundation
Foot
Health Foundation of America
Diabetic Foot
Statistics
Malaria
Foundation (Press Releases)
ORSA -
Oxacillin Resistant Staphylococcus Aureus
Pan
American Health Organization - Antimicrobal Resistance
Curable diseases from sore throats and ear infections to TB and malaria --
are in danger of becoming incurable. New report warns that increasing drug resistance
could rob the world of its opportunity to cure illnesses and stop epidemics.
Pets-MRSA
information webiste based on up to date research that informs the public and
veterinary profession about the risks of mrsa in companion animals.
Rehydrate.org - Rehydration
Project
VRSA
Interim Guidelines for Prevention and Control of Staphylococcal Infection Associated with
Reduced Susceptibility to Vancomycin
World
Health Organization - Drug Resistance
Georgia Department of
Human Resources, Division of Public Health
Methicillin-Resistant Staphylococcus aureus (MRSA)has emerged as a serious threat
in the community. Until recently, MRSA was seen almost exclusively in hospitalized
patients. Because we are now seeing it in the community, especially in pockets such as
groups of athletes, children in childcare settings and crowding situations such as prisons
and jails, the Georgia Division of Public Health is working to educate the public to
prevent this threatening infection. Click on the following links to get current
information on MRSA:
KPBS / NPR, June 2006
PBS Documentary on Superbugs
If you get sick with a bacterial infection this year, antibiotics from your doctor may
not be a fool-proof answer.
We discuss the serious medical problem of antibiotic resistance. Then, we explore the
obstacles to new antibiotic development and what this means for public health. Then, a
one-on-one interview with NPR Senior News Analyst Cokie Roberts (unrelated topic). |